Immunology & Cell BiologyPublication of the Year Awards 2016
The ASI President, together with members of the ASI Executive and the Immunology & Cell Biology Editorial Board undertake rigorous review to identify the most outstanding original research articles based on scientific excellence. The winner of the Chris and Bhama Parish ICB Publication of the Year Award is awarded an AU$1000 scholarship provided by the Nature Publishing Group and the runner-up is awarded an AU$500 scholarship provided by Thermo Fisher Scientific.
Every year an outstanding series of papers are submitted for consideration for the prizes and 2016 was no different, with an exceptional standard of science reported in the papers. It is a great pleasure to announce the winners (Figure 1) of the awards for 2016 who are as follows:
Chris and Bhama Parish ICB Publication of the Year Award: Dr Elena Shklovskaya, T Cell Biology Research Program, Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Australia; Present address: Macquarie University, North Ryde, NSW, Australia.
Thermo Fisher Scientific Publication Award: Dr E Bridie Clemens, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
The winning paper by Dr Shklovskaya is an original article entitled ‘Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen' and was published in July 2016.1 Dr Shklovskaya undertook this work when she was a member of the T cell Biology Research Program at the Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney. In this study, Dr Shklovskaya asked the key question, ‘How can CD4 T cells control tumours?' In the past, research has focused on CD8 T-cell-mediated control of cancer with the expectation that CD4 T cell help was limited to support of the CD8 T-cell response. Dr Shklovskaya takes another tack to show that not only are CD4 T cells essential in this model, they are sufficient, and thus adds strong support to the growing body of evidence that CD4 T cells can directly control tumour cells. Furthermore, by developing a mouse model in which the presentation of tumour antigen on MHC class II is restricted to host cells, Elena is able to show that tumour-specific CD4 T cells are mediating tumour clearance by indirect recognition. She identifies IFN-γ as an essential factor governing tumour clearance and determines that control of these tumours by CD4 T cells is strongest in leukopenic individuals. Taken together these findings are valuable, timely, and novel; however, what sets this study apart is the appreciation of individual patterns of tumour control and the development of novel analyses that begin to link these patterns to the underlying immune mechanisms.
Dr Clemens' original article ‘Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians' was published in April 2016, is the winner of the Thermo Fisher Scientific Publication Award for 2016.2 Dr Clemens investigates two possible explanations for why indigenous Australians are highly susceptible to severe influenza—altered CD8 T-cell immunity and enhanced frequency of an interferon-induced transmembrane protein 3 (IFITM3) allele linked to severe influenza.